- Home
- PHUN vs PSTV Comparison
PHUN vs PSTV Comparison
Compare PHUN & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | PSTV |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 27.9M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PHUN | PSTV |
|---|---|---|
| Price | $1.89 | $4.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.25 | ★ $55.00 |
| AVG Volume (30 Days) | 143.2K | ★ 4.3M |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.36 | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | $5,213,000.00 |
| Revenue This Year | $89.86 | $21.93 |
| Revenue Next Year | N/A | $279.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $0.13 |
| 52 Week High | $3.88 | $4.10 |
Technical Indicators
Market Signals| Indicator | PHUN | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 87.89 |
| Support Level | $1.79 | $0.37 |
| Resistance Level | $2.00 | N/A |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.01 | 0.45 |
| Stochastic Oscillator | 70.78 | 91.76 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).